These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34092162)

  • 21. Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab.
    Corral IS; Freitas TH; Aquino RT; Koller DA; Magliari ME; Muller H
    An Bras Dermatol; 2013; 88(4):639-42. PubMed ID: 24068143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
    Londhe PJ; Kalyanpad Y; Khopkar US
    Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
    Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
    JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.
    Antonucci A; Negosanti M; Tabanelli M; Varotti C
    J Dermatolog Treat; 2007; 18(3):178-83. PubMed ID: 17538808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up.
    Greenblatt DT; Benton EC; Groves RW; Setterfield JF
    Clin Exp Dermatol; 2016 Jul; 41(5):529-32. PubMed ID: 27061201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.
    Arin MJ; Hunzelmann N
    Eur J Dermatol; 2005; 15(4):224-30. PubMed ID: 16048747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus.
    Bozca BC; Bilgiç A; Uzun S
    J Dermatolog Treat; 2022 Jun; 33(4):2102-2109. PubMed ID: 34027788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases].
    Alter M; Wittmann M; Völker B; Kapp A; Werfel T; Gutzmer R
    Hautarzt; 2009 Sep; 60(9):743-8. PubMed ID: 19151961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study.
    Russo I; Miotto S; Saponeri A; Alaibac M
    Expert Opin Biol Ther; 2020 Jun; 20(6):673-678. PubMed ID: 32027810
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study.
    Miše J; Jukić IL; Marinović B
    Front Immunol; 2022; 13():884931. PubMed ID: 35592312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab in severe pemphigus.
    Schmidt E; Goebeler M; Zillikens D
    Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab: A Review in Pemphigus Vulgaris.
    Frampton JE
    Am J Clin Dermatol; 2020 Feb; 21(1):149-156. PubMed ID: 31838645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
    Dupuy A; Viguier M; Bédane C; Cordoliani F; Blaise S; Aucouturier F; Bonnetblanc JM; Morel P; Dubertret L; Bachelez H
    Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab.
    Ahmed AR; Shetty S
    Autoimmun Rev; 2015 Apr; 14(4):323-31. PubMed ID: 25499920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.
    Baum S; Gilboa S; Greenberger S; Pavlotsky F; Trau H; Barzilai A
    J Dermatolog Treat; 2013 Dec; 24(6):427-30. PubMed ID: 23521340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
    Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
    Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [[Treatment of therapy resistant pemphigus vulgaris with rituximab and immunoglobulins].
    Mühlhoff C; Megahed M
    Hautarzt; 2007 Nov; 58(11):924-6. PubMed ID: 17952393
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical resolution of pemphigus vulgaris on rituximab.
    Cusick E; Silverstein D
    Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in refractory pemphigus vulgaris.
    Sorce M; Aricò M; Bongiorno MR
    Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.